Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock
Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock
数字背后：7位分析师讨论莱斯康制药股票
The standing of Lexicon...In the last three months, 7 analysts have published ratings on Lexicon Pharmaceuticals (NASDAQ:LXRX), offering a diverse range of perspectives from bullish to bearish.
在过去的三个月里，有7位分析师对莱斯康制药（NASDAQ:LXRX）发布了评级，从看好到看淡，提供了多元化的观点。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他们最近的评级概况，突出了过去30天内情绪的变化，并将其与之前的月份进行了比较。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.0, a high estimate of $10.00, and a low estimate of $10.00. No alteration is observed as the current average remains at the previous average price target.
分析师通过对12个月价格目标的评估提供了更深入的见解，显示出平均目标为$10.0，最高估计为$10.00，最低估计为$10.00。当前平均值与先前平均价格目标保持不变。
Understanding Analyst Ratings: A Comprehensive Breakdown
分析师评级：全面解析
The standing of Lexicon...
通过对近...
登录免费看全文
登录/注册
资讯热榜
更新时间